CD274 and non-small cell lung carcinoma: Our group has previously revealed that among patients with advanced NSCLC with PD-L1 TPS greater than or equal to 50%, cases with a very high PD-L1 TPS greater than or equal to 90% have significantly higher objective response rate (ORR) and longer median progression-free survival (PFS) and overall survival (OS) compared with those with PD-L1 TPS of 50% to 89%.8